Vertex Pharmaceuticals Incorporated — 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. This is an annual filing, not a standalone fourth-quarter filing; quarterly figures below are unaudited. Amounts are in U.S. dollars.
Business context
Vertex discovers, develops, manufactures and commercializes medicines for serious diseases. Its marketed products were INCIVEK (telaprevir) for genotype 1 hepatitis C (HCV) and KALYDECO (ivacaftor) for cystic fibrosis (CF) patients with the G551D mutation. Vertex also received royalties on Janssen’s overseas sales of telaprevir as INCIVO. Revenue was highly concentrated in HCV: INCIVEK represented 87% of 2012 net product revenue.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Total revenue | $1.527 billion | $1.411 billion |
| Net product revenue | $1.333 billion | $950.9 million |
| INCIVEK revenue | $1.162 billion | $950.9 million |
| KALYDECO revenue | $171.6 million | Not yet marketed |
| Royalty revenue | $141.5 million | $50.0 million |
| Collaborative revenue | $52.1 million | $409.7 million |
| Operating income | $2.3 million | $113.8 million |
| Net income (loss) attributable to Vertex | $(107.0) million | $29.6 million |
| Net income (loss) per diluted share attributable to Vertex | $(0.50) | $0.14 |
| Net cash provided by operating activities | $267.8 million | $143.7 million |
| Cash, cash equivalents and marketable securities | $1.321 billion | $968.9 million |
Operating income was about 0.2% of revenue. Vertex’s consolidated net loss was $51.1 million; the larger $107.0 million loss attributable to Vertex reflects the accounting allocation for Alios, its consolidated collaborator. Operating expenses rose 18% to $1.525 billion, including R&D expense of $806.2 million and SG&A expense of $436.8 million. The filing reports no separate gross-margin percentage.
Operating cash flow was $267.8 million; cash expenditures for property and equipment were $71.1 million. The company reported $400 million of 3.35% convertible senior subordinated notes due October 2015. It also recorded a $268.0 million construction financing lease obligation for its Boston headquarters project. Total contractual commitments and obligations were $1.916 billion, including $1.026 billion for the Fan Pier leases. Alios’s restricted cash is not available to fund Vertex’s operations.
Fourth-quarter results and changes versus prior periods
In Q4 2012, total revenue was $334.0 million, including $281.3 million in product revenue, $43.5 million in royalties and $9.2 million in collaborative revenue. Product revenue included $222.8 million of INCIVEK and $58.5 million of KALYDECO. Vertex reported a $77.5 million operating loss and a $76.1 million net loss attributable to Vertex, or $(0.35) per diluted share.
Full-year revenue increased 8% from 2011, but the mix changed sharply: product and royalty revenue increased, while collaborative revenue fell 87%, largely because 2011 included $250 million in Janssen milestones and other nonrecurring collaboration revenue. INCIVEK revenue declined quarter by quarter after peaking in Q4 2011, despite higher full-year sales due to a full year of sales in 2012 versus a partial year in 2011. KALYDECO revenue grew through 2012. Vertex recorded $133.2 million of excess and obsolete INCIVEK inventory charges in 2012, compared with no such charge in 2011.
Outlook, management commentary and material risks
- Management expected total revenue and total product revenue to decline in 2013 as INCIVEK sales fell; it expected KALYDECO revenue to increase, but not enough in the near term to offset the expected INCIVEK decline. No numerical 2013 revenue guidance is provided in the filing.
- Vertex expected R&D expense to increase in 2013 due to planned CF, HCV and autoimmune-disease trials, and SG&A expense to decrease. It stated current cash, equivalents, securities and expected product and royalty cash flows should fund operations for at least 12 months.
- HCV competition and changing treatment practices are a central risk. Management anticipated newer regimens could reach the market in 2013–2014 and potentially take significant share; all-oral regimens could weaken demand for interferon-based treatment. INCIVEK also received a U.S. Boxed Warning in December 2012 for reported fatal and non-fatal serious skin reactions.
- CF development is a key opportunity and execution risk. Vertex began pivotal Phase 3 trials of VX-809 plus ivacaftor in February 2013, with final 24-week data expected in 2014 and potential U.S. and European filings that year if successful. These expectations are forward-looking, not assured outcomes.
- Other significant risks include uncertain clinical and regulatory results; reimbursement and pricing outcomes for KALYDECO abroad; reliance on third-party and sole-source manufacturers; possible further INCIVEK inventory write-downs; and potential impairment of $663.5 million in HCV-related intangible assets if VX-135 or VX-222 prospects deteriorate.
- A shareholder class action filed in 2012 alleges material misstatements or omissions in company disclosures; Vertex said it believed the action was without merit and intended to defend it. No reserve was recorded at year-end.
- Vertex planned a complex headquarters move to Boston in 2013–2014. The long-term Fan Pier lease commitments and potential operational disruption are relevant to execution and cash needs.
Important facts for investors to verify
- Track quarterly INCIVEK demand, revenue and inventory levels, including any additional write-downs, alongside the timing and market uptake of competing HCV therapies.
- Check KALYDECO international reimbursement decisions, net pricing and sales growth against management’s expectations.
- Review Phase 3 VX-809/ivacaftor results and label-expansion trial data, including safety, efficacy and regulatory timelines.
- Assess available liquidity excluding Alios restricted cash, operating cash flow, the 2015 note repayment or conversion terms, and substantial lease commitments.
- Monitor valuation assumptions and impairment exposure for VX-135 and VX-222, as well as Alios-related contingent payments and royalties.
- Review the serious-skin-reaction warning, the shareholder litigation, and any material developments in manufacturing supply or reimbursement.